Both c-Myc and Ki-67 expression are predictive markers in patients with Extranodal NK/T-cell lymphoma, nasal type: A retrospective study in China

Pathology Research and Practice

Volumn 210, Issue 6, 2014, Pages 351-356

  Huang, Xiaoyin ^a   Sun, Qian ^a   Fu, Haijin ^a   Zhou, Xiaojun ^a   Guan, Xiaoxiang ^a   Wang, Jinghua ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

C Myc; Extranodal NK T cell lymphoma; Ki 67; Prognosis

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY KI 67; MYC PROTEIN; KI 67 ANTIGEN; MYC PROTEIN, HUMAN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CHINA; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; ADOLESCENT; CHEMISTRY; CHILD; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; UPREGULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL PROLIFERATION; CHILD; CHINA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 84899475030     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.02.004     Document Type: Article

References (18)

1. Suzuki R. NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm. Curr. Oncol. Rep. 2012, 14(5):395-402.
2. Lee J., Suh C., Park Y.H., et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol. 2006, 24(4):612-618.
3. Dearden C.E., Johnson R., Pettengell R., et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br. J. Haematol. 2011, 153(4):451-485.
4. Hu F., Gartenhaus R.B., Zhao X.F., et al. c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas. Leuk. Res. 2013, 37(4):447-454.
5. Scheller H., Tobollik S., Kutzera A., et al. c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma. Oncogene 2010, 29(6):888-897.
6. Kluk M.J., Chapuy B., Sinha P., et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PloS ONE 2012, 7(4):e33813.
7. Huang Y.L., de Reynies A., de Leval L., et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma: nasal type. Blood 2010, 115(6):1226-1237.
8. Iqbal J., Kucuk C., deLeeuw R.J., et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia 2009, 23(6):1139-1151.
9. Yasuda H., Sugimoto K., Imai H., et al. Expression levels of apoptosis-related proteins and Ki-67 in nasal NK/T-cell lymphoma. Eur. J. Haematol. 2009, 82(1):39-45.
10. Yoon D.H., Choi D.R., Ahn H.J., et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur. J. Haematol. 2010, 85(2):149-157.
11. Stein H.C.J., Warnke R.A., Gatter K.C., Chan W.C., Campo E., Jaffe E.S. Extranodal NK/T-cell lymphoma, nasal type. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 285-288. WHO, Geneva. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
12. Pelengaris S., Khan M. Evan G. c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2002, 2(10):764-776.
13. Morrish F., Isern N., Sadilek M., et al. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 2009, 28(27):2485-2491.
14. Todorovic-Rakovic N., Neskovic-Konstantinovic Z., Nikolic-Vukosavljevic D. c-Myc as a predictive marker for chemotherapy in metastatic breast cancer. Clin. Exper. Med. 2012, 12(4):217-223.
15. Smith S.M., Anastasi J., Cohen K.S., et al. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cells Mol. Dis. 2010, 45(4):317-323.
16. Kobayashi T., Tsutsumi Y., Sakamoto N., et al. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab. Jpn. J. Clin. Oncol. 2012, 42(11):1035-1042.
17. Ng S.B., Selvarajan V., Huang G.F., et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J. Pathol. 2011, 223(4):496-510.
18. Kim S.J., Kim B.S., Choi C.W., et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma: nasaltype. Ann. Oncol. 2007, 18(8):1382-1387.